Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 14Lymphoid 6Genitourinary 5Other hematologic neoplasm 3Gastrointestinal 2Thoracic 1Other solid neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1Classical hematology 1

Conditions

Thrombocytosis 1Thrombocytopenia 1Primary Myelofibrosis 1Polycythemia Vera 1Lymphoma, Follicular 1Anemia 1

Interventions

Cyclophosphamide 259fludarabine phosphate 232Azacitidine 180fludarabine 179Busulfan 174Cytarabine 154Mycophenolic Acid 147Tacrolimus 145Whole-Body Irradiation 141Imatinib Mesylate 141Peripheral Blood Stem Cell Transplantation 139Cyclosporine 110Antilymphocyte Serum 108Melphalan 106Methotrexate 105Filgrastim 101Decitabine 98nilotinib 82venetoclax 77ruxolitinib 72Granulocyte Colony-Stimulating Factor 66Stem Cell Transplantation 62Dasatinib 62Thiotepa 60Radiotherapy 60thymoglobulin 52Specimen Handling 49Etoposide 49Clofarabine 46Cord Blood Stem Cell Transplantation 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × siltuximab × Myeloid × Clear all
NCT02805868 2016-10-24

Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Northwestern University

Phase EARLY_PHASE1 Withdrawn
Classical hematologyLymphoidMyeloid

Anemia, Lymphoma, Follicular, Polycythemia Vera, Thrombocytopenia, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡